An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO) (IMMagine)
Status
Active, not recruiting
Conditions
Psoriasis
Details and patient eligibility
About
The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation study up to 28 weeks. The treatment decision for RZB must be made independent of this study enrollment.
Enrollment
150 estimated patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a dermatologist and presence of moderate to severe psoriasis symptoms according to physician's clinical judgment at the time of recruitment.
- Participants initiating RZB treatment for psoriasis as per local label. Physician's decision for treatment with risankizumab must have been reached prior to and independently of recruitment in the study.
- Participants able to understand and communicate with the investigator and comply with the requirements of the study.
- Willingness and ability to comply with all study requirements.
Exclusion criteria
- Current or recent (within the last 30 days) participation in an interventional clinical trial.
Trial design
150 participants in 1 patient group
Risankizumab
Description:
Participants will receive risankizumab as prescribed by their physician according to local label.
Trial contacts and locations
17
Loading...
Central trial contact
Simone Rubant
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems